Application of a novel boronated porphyrin as a dual sensitizer for both PDT and BNCT
Project/Area Number |
15K19982
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Neurosurgery
|
Research Institution | Osaka Medical College |
Principal Investigator |
Hiramatsu Ryo 大阪医科大学, 医学部, 助教 (40609707)
|
Research Collaborator |
M. Graça H. Vicente Louisiana State University, Department of Chemistry
|
Project Period (FY) |
2015-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Keywords | 悪性神経膠腫 / BNCT / PDT / ホウ素化ポルフィリン / CED / ホウ素化クロリン / ホウ素中性子捕捉療法 / 光線力学的療法 |
Outline of Final Research Achievements |
In this study, H2OCP as a novel boronated porphyrin has been proven to be a promising photosensitizer for PDT. H2OCP has also been proposed as a potentially effective replacement of BPA or BSH, or as a replacement of both BPA/BSH. This study provides more evidence that H2OCP could be an effective novel dual sensitizing agent for use in both PDT and BNCT. And Boronated chlorin as well as a boronated porphyrin is a large-ring compound and has a tumor affinity. So, boronated chlorin has also been proven to be a dual sensitizing agent for use in both PDT and BNCT. In this study, we also searched a useful drug for a dual sensitizing agent.
|
Report
(3 results)
Research Products
(12 results)
-
[Journal Article] Evaluation of a novel sodium borocaptate-containing unnatural amino acid as a boron delivery agent for neutron capture therapy of the F98 rat glioma2017
Author(s)
Futamura G, Kawabata S, Nonoguchi N, Hiramatsu R, Toho T, Tanaka H, Masunaga SI, Hattori Y, Kirihata M, Ono K, Kuroiwa T, Miyatake SI
-
Journal Title
Radiat Oncol.
Volume: 12
Issue: 1
Pages: 26-26
DOI
NAID
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-
-
-
-
-
-
-
-
-